日前，总部位于美国加州的Alamar Biosciences（下称“Alamar”）宣布完成8000万美元B轮融资，启明创投继续投资。公司成立至今已经完成总计1.1亿美元融资。

本轮融资将进一步加速Alamar的自有蛋白质组技术的开发落地，在全自动一体化平台上同时实现超高灵敏度、超多重以及更宽的动态检测范围。Alamar的蛋白质组技术未来可以在多个领域赋能下游客户，包括生命科学研究、液态活检以及新药研发等场景。

Alamar由一群经验丰富的连续创业者于2018年创立。公司联合创始人兼CEO Dr.Yuling Luo以及联合创始人兼COO Dr.Steve Chen，此前曾一同创立了Advanced Cell Diagnostics (ACD)，成功研发并商业化了全球领先的RNA原位杂交技术平台RNAscope，ACD于2016年被Bio-Techne收购。Alamar联合创始人兼技术副总裁Dr. Yiyuan Yin在蛋白质工程和结构生物学方面具备丰富经验。

Alamar的蛋白质组技术同时融合了独创的单分子检测技术NULISATM，以及抗体工程技术AttobodyTM。该技术平台将为生命科学和新药研究者提供一次样本同时检测超多重标志物（>1000X）并同时实现超高灵敏度（aM级别）的解决方案。同时该技术也将为肿瘤无创早筛等临床未满足需求提供新的诊断工具。

对于本轮融资，Dr.Yuling Luo表示：“我们非常高兴得到行业内一流投资机构的支持，加速我们下一阶段的产品开发和商业化落地。近年来，蛋白和蛋白质组检测领域不断有新技术的突破，但我们发现很少有技术可以在一个自动化平台上同时兼顾高灵敏度和超多重检测。Alamar的NULISA和Attobody技术平台可以帮助填补这一方面的未满足需求，将下一代蛋白质组技术带入科研，诊断和新药研发领域。”

启明创投投资合伙人唐艳旻表示：“我们很高兴能继续支持Alamar，公司在过去两年取得了长足发展。Alamar正在筹备研究仪器与试剂、诊断及抗体治疗三条业务线，我们相信这会给医疗健康行业带来重大长期价值。”

本轮融资由夏尔巴投资领投，Morningside Ventures和Samsara Biocapital跟投，老股东启明创投和Illumina Ventures持续投资。

This oversubscribed round of investment will accelerate the development of Alamar's proprietary proteomics platform, which will be the most sensitive, highly multiplexed, and high dynamic range solution for life science research, pharmaceutical development, and diagnostics such as liquid biopsy. The platform leverages Next Generation Sequencing to bring the power of genomics to proteomics, enabling the early detection of cancer and other diseases.

"We are very pleased to have these top-tier investors supporting our next phase of development. They bring tremendous amount of expertise in life sciences and diagnostics, which will be extremely valuable to us as we build the company," said Dr. Yuling Luo, Founder, Chairman and CEO. "Despite recent progress in the field, there is still no technology that unites two essential goals in proteomics analysis, namely the ability to go as deeply as possible to detect very low abundance proteins and the ability to profile thousands of proteins in a single sample. This capability will be critical for the discovery and measurement of many proteins in human plasma that are currently undetectable. Alamar's NULISA and Attobody platforms will help fill this void and will drive a new wave of innovations in research, diagnostics, and therapeutics."

Alamar Biosciences was founded by Dr. Luo, a technologist and serial entrepreneur who previously founded Advanced Cell Diagnostics (ACD), now a part of Bio-Techne, and led it as President and CEO. At ACD he pioneered the field of spatial genomics together with Dr. Xiao-Jun Ma by inventing and successfully commercializing RNAscope, the world's most sensitive RNA in situ detection technology. Recognizing a similar critical need for ultra-sensitive protein detection technology in proteomics, Dr. Luo started Alamar Biosciences with Dr. Steve Chen, who was also a co-founder of ACD, and Dr. Yiyuan Yin, a structural biologist with extensive antibody engineering expertise.

The Alamar Biosciences team has applied their insights gained from developing single-molecule detection technologies and antibody engineering to create two technology platforms – NULISA™ and Attobody™ . The combination of these ground-breaking platforms provides the unique ability to detect extremely low levels of protein biomarkers in human blood plasma, and to do so in a high-plex format allowing for the measurement of thousands of protein targets in a single assay, leading to a new generation of noninvasive precision diagnostics.

"We are pleased to continue our support of Alamar, which has made excellent progresses in the past two years. With three potential lines of business - research instruments and reagents, diagnostics, and antibody therapeutics - we believe the company is well-positioned to make a significant impact on the future of healthcare," said Amy Tang, Venture Partner of the company's Series A lead investor, Qiming Venture Partners.

The Series B financing round was led by Sherpa Healthcare Partners and included Morningside Ventures, Samsara Biocapital, and existing investors Qiming Venture Partners and Illumina Ventures.

往期回顾

启明荣誉 | 史上最强！启明创投荣获清科年度中国创业投资机构第五名

启明荣誉 | 启明创投及主管合伙人梁颕宇荣登2021中国基金合伙人年度系列榜单

启明观点 | 启明创投唐艳旻：义翘神州兼具核心技术优势和极强的社会责任感

启明创投成立于2006年，先后在上海、北京、苏州、香港，西雅图、波士顿和旧金山湾区设立办公室。

目前，启明创投旗下管理九只美元基金，六只人民币基金，管理资产总额达到59亿美元。自成立至今，专注于投资TMT 、医疗健康 （Healthcare） 等行业早期和成长期的优秀企业。

截至目前，启明创投已投资超过380家高速成长的创新企业，其中有超过130家分别在美国纽交所、纳斯达克，香港联交所，台湾柜买中心，上交所及深交所等交易所上市，及合并等退出，有40多家企业成为行业公认的独角兽和超级独角兽企业。